Atrial Fibrillation - Pipeline Review, H1 2016

Published: Feb, 2016 | Pages: 102 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Atrial Fibrillation - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Atrial Fibrillation - Pipeline Review, H1 2016', provides an overview of the Atrial Fibrillation pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Atrial Fibrillation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Atrial Fibrillation and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Atrial Fibrillation
- The report reviews pipeline therapeutics for Atrial Fibrillation by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Atrial Fibrillation therapeutics and enlists all their major and minor projects
- The report assesses Atrial Fibrillation therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Atrial Fibrillation

Reasons to Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Atrial Fibrillation
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Atrial Fibrillation pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Atrial Fibrillation Overview 9
Therapeutics Development 10
Pipeline Products for Atrial Fibrillation - Overview 10
Pipeline Products for Atrial Fibrillation - Comparative Analysis 11
Atrial Fibrillation - Therapeutics under Development by Companies 12
Atrial Fibrillation - Therapeutics under Investigation by Universities/Institutes 13
Atrial Fibrillation - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Atrial Fibrillation - Products under Development by Companies 17
Atrial Fibrillation - Products under Investigation by Universities/Institutes 19
Atrial Fibrillation - Companies Involved in Therapeutics Development 20
ARCA biopharma, Inc. 20
AstraZeneca Plc 21
Bristol-Myers Squibb Company 22
Cardiome Pharma Corp. 23
Daiichi Sankyo Company, Limited 24
Gilead Sciences, Inc. 25
Ionis Pharmaceuticals, Inc. 26
Laboratoires Pierre Fabre SA 27
Nissan Chemical Industries, Ltd. 28
Nyken B.V. 29
Otsuka Holdings Co., Ltd. 30
Perrigo Company Plc 31
Xention Limited 32
Atrial Fibrillation - Therapeutics Assessment 33
Assessment by Monotherapy Products 33
Assessment by Target 34
Assessment by Mechanism of Action 36
Assessment by Route of Administration 38
Assessment by Molecule Type 40
Drug Profiles 42
AFC-1 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
BMS-394136 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
BMS-919373 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
bucindolol hydrochloride - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
edoxaban tosylate - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
F-373280 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
flecainide acetate - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
GS-967 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
ISIS-CRPRx - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
landiolol - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
NIP-151 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
NYK-1112 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
OMT-28 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
OPC-108459 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
ranolazine ER - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Small Molecule to Block Calcium-Activated Potassium Channel for Atrial Fibrillation - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Small Molecule to Block Kv1.5 for Atrial Fibrillation - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Small Molecules to Block Voltage Gated Sodium Channel for Atrial Fibrillation - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
vernakalant hydrochloride - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
XEN-R0702 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
XEND-0103 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
XENR-0703 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
XENR-0706 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
Atrial Fibrillation - Recent Pipeline Updates 72
Atrial Fibrillation - Dormant Projects 87
Atrial Fibrillation - Discontinued Products 91
Atrial Fibrillation - Product Development Milestones 92
Featured News & Press Releases 92
Jan 27, 2016: Cardiome Announces Filing of Orphan Drug Application for Oral Vernakalant with U.S. FDA 92
Jan 13, 2016: Cardiome announces filing of marketing authorization application for intravenous vernakalant in the Kingdom Of Saudi Arabia 92
Dec 22, 2015: Cardiome Files New Drug Submission Seeking Canadian Approval Of Intravenous Vernakalant 92
Nov 02, 2015: Daiichi Sankyo, Inc. Announces New Subgroup Analyses of Once-Daily SAVAYSA in Patients with Non-Valvular Atrial Fibrillation Will Be Presented at AHA Scientific Sessions 2015 93
Nov 02, 2015: OMEICOS Receives BMBF Research Grant to Advance its Novel Approach to Treat Atrial Fibrillation 94
Sep 23, 2015: UK's NICE recommends once-daily LIXIANA (edoxaban) for preventing stroke and systemic embolism in patients with non-valvular atrial fibrillation 94
Aug 10, 2015: United Kingdom Department of Health Sets BRINAVESS Pricing 96
Jul 24, 2015: Cardiome Partner Eddingpharm to Initiate BRINAVESS Phase I Study in China 96
Jul 09, 2015: New Therapy to Help Heart Rhythm Patients Means Doctors are "Spoilt for Choice" 96
Jun 25, 2015: Daiichi Sankyo's Once-Daily LIXIANA (edoxaban) Approved in the EU for Stroke Prevention in Nonvalvular Atrial Fibrillation and for the Treatment and Prevention of Recurrent DVT and PE 99
Appendix 101
Methodology 101
Coverage 101
Secondary Research 101
Primary Research 101
Expert Panel Validation 101
Contact Us 101
Disclaimer 102

List of Tables
Number of Products under Development for Atrial Fibrillation, H1 2016 10
Number of Products under Development for Atrial Fibrillation - Comparative Analysis, H1 2016 11
Number of Products under Development by Companies, H1 2016 12
Number of Products under Investigation by Universities/Institutes, H1 2016 13
Comparative Analysis by Late Stage Development, H1 2016 14
Comparative Analysis by Clinical Stage Development, H1 2016 15
Comparative Analysis by Early Stage Development, H1 2016 16
Products under Development by Companies, H1 2016 17
Products under Development by Companies, H1 2016 (Contd..1) 18
Products under Investigation by Universities/Institutes, H1 2016 19
Atrial Fibrillation - Pipeline by ARCA biopharma, Inc., H1 2016 20
Atrial Fibrillation - Pipeline by AstraZeneca Plc, H1 2016 21
Atrial Fibrillation - Pipeline by Bristol-Myers Squibb Company, H1 2016 22
Atrial Fibrillation - Pipeline by Cardiome Pharma Corp., H1 2016 23
Atrial Fibrillation - Pipeline by Daiichi Sankyo Company, Limited, H1 2016 24
Atrial Fibrillation - Pipeline by Gilead Sciences, Inc., H1 2016 25
Atrial Fibrillation - Pipeline by Ionis Pharmaceuticals, Inc., H1 2016 26
Atrial Fibrillation - Pipeline by Laboratoires Pierre Fabre SA, H1 2016 27
Atrial Fibrillation - Pipeline by Nissan Chemical Industries, Ltd., H1 2016 28
Atrial Fibrillation - Pipeline by Nyken B.V., H1 2016 29
Atrial Fibrillation - Pipeline by Otsuka Holdings Co., Ltd., H1 2016 30
Atrial Fibrillation - Pipeline by Perrigo Company Plc, H1 2016 31
Atrial Fibrillation - Pipeline by Xention Limited, H1 2016 32
Assessment by Monotherapy Products, H1 2016 33
Number of Products by Stage and Target, H1 2016 35
Number of Products by Stage and Mechanism of Action, H1 2016 37
Number of Products by Stage and Route of Administration, H1 2016 39
Number of Products by Stage and Molecule Type, H1 2016 41
Atrial Fibrillation Therapeutics - Recent Pipeline Updates, H1 2016 72
Atrial Fibrillation - Dormant Projects, H1 2016 87
Atrial Fibrillation - Dormant Projects (Contd..1), H1 2016 88
Atrial Fibrillation - Dormant Projects (Contd..2), H1 2016 89
Atrial Fibrillation - Dormant Projects (Contd..3), H1 2016 90
Atrial Fibrillation - Discontinued Products, H1 2016 91